Demographic characteristics with significant differences between HRVO versus BRVO and HRVO versus CRVO in bold (p<0.05)
| HRVO | BRVO | P value (vs HRVO) | CRVO | P value (vs HRVO) | |
| Eyes, n | 79 | 590 | 344 | ||
| Patients, n | 78 | 580 | 344 | ||
| Gender, % female | 48 | 51 | 0.75 | 41 | 0.31 |
| Age, mean years (SD) | 71 (11) | 70 (11) | 0.53 | 70 (12) | 0.68 |
| VA, mean letters (SD) | 53.8 (17.7) | 59.4 (14.9) | 0.009 | 51.9 (18.7) | 0.40 |
| VA ≥70 letters, % | 24 | 32 | 0.15 | 21 | 0.54 |
| VA ≤35 letters, % | 20 | 9 | 0.007 | 22 | 0.88 |
| CST, mean microns (SD) | 550 (186) | 482 (159) | 0.004 | 630 (223) | 0.002 |
| Initial treatment | |||||
| Bevacizumab | 33% | 32% | 0.90 | 26% | 0.27 |
| Ranibizumab | 37% | 39% | 0.71 | 41% | 0.52 |
| Aflibercept | 30% | 29% | 0.79 | 32% | 0.79 |
P values reflect comparison of HRVO versus BRVO or comparison of HRVO versus CRVO.
BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; CST, central subfield thickness; HRVO, hemiretinal vein occlusion; VA, visual acuity.